Cargando…
The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent
Background: Albumin is a critical component in the standard therapeutic approach to acute renal failure (ARF) and spontaneous bacterial peritonitis (SBP) in the setting of ascites. However, data regarding the safety and minimum effective dose are limited. Methods: We conducted a retrospective review...
Autores principales: | Afinogenova, Yuliya, Tapper, Elliot B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527271/ https://www.ncbi.nlm.nih.gov/pubmed/26178624 http://dx.doi.org/10.1093/gastro/gov032 |
Ejemplares similares
-
Optimal management of hepatorenal syndrome in patients with cirrhosis
por: Angeli, Paolo, et al.
Publicado: (2010) -
Acute kidney injury and hepatorenal syndrome in cirrhosis
por: Gupta, Kapil, et al.
Publicado: (2021) -
Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016) -
Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis
por: Salerno, Francesco, et al.
Publicado: (2015) -
Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome
por: Bucsics, Theresa, et al.
Publicado: (2017)